Actemra market seen rising to $9.34 million by 2030

The global Actemra (tocilizumab) market is projected to grow from $5.71 million in 2025 to $6.32 million in 2026, then reach $9.34 million by 2030, according to The Business Research Company. Rising rheumatoid arthritis cases, broader biologic use and expanding access to autoimmune treatments are driving demand, with North America leading today and Asia-Pacific expected to grow fastest.

Why it matters: - Actemra is used to treat autoimmune and inflammatory diseases, including rheumatoid arthritis, giant cell arteritis and cytokine release syndrome. - The market’s growth reflects wider demand for biologic therapies that target inflammation more precisely than older treatments. - Rising disease burden could expand use in hospitals, infusion centers and other care settings.

What happened: - The Business Research Company published its Actemra (Tocilizumab) Global Market Report 2026 on Oct. 29, 2026. - The report projects the global Actemra market will grow from $5.71 million in 2025 to $6.32 million in 2026. - The report forecasts the market will reach $9.34 million by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Download a free sample of the market report - View the full market report

The details: - Actemra, also known as tocilizumab, is a prescription biologic drug classified as an IL-6 receptor antagonist. - The drug blocks interleukin-6, a cytokine that helps drive inflammation. - The report links historic market growth to the established role of IL-6 in inflammation, rising rheumatoid arthritis cases, positive clinical trial results, broader biologic use in tertiary hospitals and multiple regulatory approvals. - The report says future growth will be supported by the rising burden of autoimmune diseases, broader use in new inflammatory conditions, growth in biologic infusion centers, earlier diagnosis and better access to biologic therapies. - The report highlights expanded use in autoimmune and inflammatory disorders, greater adoption for cytokine release syndrome, more hospital-based biologic administration, earlier IL-6 inhibitor intervention and stronger long-term safety monitoring as key trends. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says its 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated trend analysis. - The company said the report also includes graphics and tables.

Between the lines: - The strongest driver in the release is rheumatoid arthritis prevalence, which keeps expanding the pool of patients who may need biologic treatment. - The regional split suggests mature demand in North America and faster adoption potential in markets still expanding healthcare access. - The report’s emphasis on infusion centers and hospital administration points to treatment delivery infrastructure as a market constraint and opportunity.

What's next: - The market is projected to grow at a 10.3% CAGR through 2030. - Wider use of Actemra in autoimmune and inflammatory indications could support additional demand if clinical adoption continues. - Improved diagnosis and access to biologics may further lift treatment volumes, especially in faster-growing regions. - For more information, contact Saumya Sahay at marketing@tbrc.info or visit The Business Research Company.